Remove 2026 Remove FDA Remove Side effects
article thumbnail

Jazz Pharma uses flying pig for huge grey area DTC

World of DTC Marketing

billion by 2026. Given that most obstructive sleep apnea patients are obese men, it’s dangerous that the side effects listed for Sunosi say, “tell your doctor if you have heart problems, high blood pressure, kidney problems, diabetes, or high cholesterol.”

Pharma 181
article thumbnail

BMS strikes $14bn deal for Karuna Therapeutics

European Pharmaceutical Review

It has demonstrated improvements in cognition and is not associated with common side effects of currently approved treatments like weight gain. Currently under review by the US Food and Drug Administration (FDA), KarXT is expected to launch in the US in late 2024.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Sanofi looks east with €300m Innovent cancer alliance

pharmaphorum

SAR444245, meanwhile, is a long-acting IL-2 that blocks off part of the molecule that engages with alpha receptors, designed to maintain the anticancer efficacy of the molecule while preventing side effects. It is being tested in a wide range of solid tumours and lymphoma, alone and in combination with other drugs.

article thumbnail

Key Developments from AMCP 2023 on Blockbuster Generics, Diabetes Drugs, PBM Legislation, and More

PM360

A generic here will improve access in OAB to a product with less side effects, which is especially important in the elderly population, Casberg noted. In March, the FDA approved several new naloxone products using the pathway, including one from Amphastar, which will compete with other intranasal on the market.

article thumbnail

FDA makes moves to advance ALS research ahead of upcoming Amylyx AdCom

Pharmaceutical Technology

In the lead-up to a critical meeting that will influence the approval of a new drug for amyotrophic lateral sclerosis (ALS), the US Food and Drug Administration (FDA) has detailed its plans to advance rare neurodegenerative disease research. The Act authorizes the appropriation of $100,000,000 per fiscal year from 2022 to 2026.

FDA 98